Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

BACKGROUND: The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance. To elucidate the mechanisms responsible for cytarabine resistance, and to c...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMC Cancer
Main Authors: Freiburghaus, Catja, Emruli, Venera Kuci, Johansson, Angelica, Eskelund, Christian Winther, Grønbæk, Kirsten, Olsson, Roger, Ek, Fredrik, Jerkeman, Mats, Ek, Sara
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2018
Fag:
Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5918903/
https://ncbi.nlm.nih.gov/pubmed/29695239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4346-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker